{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:01:52Z","timestamp":1791910912487,"version":"4.3.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T00:00:00Z","timestamp":1670198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T00:00:00Z","timestamp":1670198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Guangdong basic and Applied Basic Research Fund Natural Science Foundation Projects","award":["2021A1515012524"],"award-info":[{"award-number":["2021A1515012524"]}]},{"name":"Science and Technology Program of Guangzhou, China","award":["202002030433"],"award-info":[{"award-number":["202002030433"]}]},{"name":"Characteristic Innovation Project of Ordinary Colleges and Universities in Guangdong Province, China","award":["2019KTSCX030"],"award-info":[{"award-number":["2019KTSCX030"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chin Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hypoxia-induced pulmonary hypertension (HPH) is one of the fatal pathologies developed under hypobaric hypoxia and eventually leads to right ventricular (RV) remodeling and RV failure. Clinically, the mortality rate of RV failure caused by HPH is high and lacks effective drugs. Xinyang Tablet (XYT), a traditional Chinese medicine exhibits significant efficacy in the treatment of congestive heart failure and cardiac dysfunction. However, the effects of XYT on chronic hypoxia-induced RV failure are not clear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The content of XYT was analyzed by high-performance liquid chromatography-tandem mass spectrometry (HPLC\u2013MS). Sprague\u2013Dawley (SD) rats were housed in a hypobaric chamber (equal to the parameter in altitude 5500\u00a0m) for 21\u00a0days to obtain the RV remodeling model. Electrocardiogram (ECG) and hemodynamic parameters were measured by iWorx Acquisition &amp; Analysis System. Pathological morphological\u00a0changes in the RV and pulmonary vessels were observed by H&amp;E staining and Masson\u2019s trichrome staining. Myocardial apoptosis was tested by TUNEL assay. Protein expression levels of TNF-\u03b1, IL-6, Bax, Bcl-2, and caspase-3 in the RV and H9c2 cells were detected by western blot. Meanwhile, H9c2 cells were induced by CoCl\n                      <jats:sub>2<\/jats:sub>\n                      to establish a hypoxia injury model to verify the protective effect and mechanisms of XYT. A CCK-8 assay was performed to determine the viability of H9c2 cells. CoCl\n                      <jats:sub>2<\/jats:sub>\n                      -induced apoptosis was detected by Annexin-FITC\/PI flow cytometry and Hoechst 33,258 staining.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      XYT remarkably improved RV hemodynamic disorder and ECG parameters. XYT attenuated hypoxia-induced pathological injury in RV and pulmonary vessels. We also observed that XYT treatment decreased the expression levels of TNF-\u03b1, IL-6, Bax\/Bcl-2 ratio, and the numbers of myocardial apoptosis in RV. In H9c2 myocardial hypoxia model, XYT protected H9c2 cells against Cobalt chloride (CoCl\n                      <jats:sub>2<\/jats:sub>\n                      )-induced apoptosis. We also found that XYT could antagonize CoCl\n                      <jats:sub>2<\/jats:sub>\n                      -induced apoptosis through upregulating Bcl-2, inhibiting Bax and caspase-3 expression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      We concluded that XYT improved hypoxia-induced RV remodeling and protected against cardiac injury by inhibiting apoptosis pathway in vivo and\n                      <jats:italic>vitro<\/jats:italic>\n                      models, which may be a promising therapeutic strategy for clinical management of hypoxia-induced cardiac injury.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13020-022-00689-2","type":"journal-article","created":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T02:03:04Z","timestamp":1670205784000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Xinyang Tablet attenuates chronic hypoxia-induced right ventricular remodeling via inhibiting cardiomyocytes apoptosis"],"prefix":"10.1186","volume":"17","author":[{"given":"An-Ran","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Cui","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-Jin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Cao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You-Zhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,5]]},"reference":[{"key":"689_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2174\/1874192401610010019","volume":"10","author":"AE Mirrakhimov","year":"2016","unstructured":"Mirrakhimov AE, Strohl KP. High-altitude pulmonary hypertension: an update on disease pathogenesis and management. Open Cardiovasc Med J. 2016;10:19\u201327.","journal-title":"Open Cardiovasc Med J"},{"key":"689_CR2","doi-asserted-by":"publisher","first-page":"13S","DOI":"10.1378\/chest.09-2445","volume":"137","author":"MA Pasha","year":"2010","unstructured":"Pasha MA, Newman JH. High-altitude disorders: pulmonary hypertension: pulmonary vascular disease: the global perspective. Chest. 2010;137:13S-19S.","journal-title":"Chest"},{"key":"689_CR3","doi-asserted-by":"publisher","first-page":"6421","DOI":"10.3390\/ijms21176421","volume":"21","author":"E Pena","year":"2020","unstructured":"Pena E, Brito J, El Alam S, Siques P. Oxidative stress, kinase activity and inflammatory implications in right ventricular hypertrophy and heart failure under hypobaric hypoxia. Int J Mol Sci. 2020;21:6421.","journal-title":"Int J Mol Sci"},{"key":"689_CR4","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.015708","author":"D Sharifi Kia","year":"2020","unstructured":"Sharifi Kia D, Benza E, Bachman TN, Tushak C, Kim K, Simon MA. Angiotensin receptor-neprilysin inhibition attenuates right ventricular remodeling in pulmonary hypertension. J Am Heart Assoc. 2020. https:\/\/doi.org\/10.1161\/JAHA.119.015708.","journal-title":"J Am Heart Assoc"},{"key":"689_CR5","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1089\/ars.2007.1587","volume":"9","author":"IR Preston","year":"2007","unstructured":"Preston IR. Clinical perspective of hypoxia-mediated pulmonary hypertension. Antioxid Redox Signal. 2007;9:711\u201321.","journal-title":"Antioxid Redox Signal"},{"key":"689_CR6","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.cjca.2015.01.023","volume":"31","author":"JJ Ryan","year":"2015","unstructured":"Ryan JJ, Huston J, Kutty S, Hatton ND, Bowman L, Tian L, Herr JE, Johri AM, Archer SL. Right ventricular adaptation and failure in pulmonary arterial hypertension. Can J Cardiol. 2015;31:391\u2013406.","journal-title":"Can J Cardiol"},{"key":"689_CR7","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1161\/CIRCRESAHA.113.301129","volume":"115","author":"JJ Ryan","year":"2014","unstructured":"Ryan JJ, Archer SL. The right ventricle in pulmonary arterial hypertension: disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure. Circ Res. 2014;115:176\u201388.","journal-title":"Circ Res"},{"key":"689_CR8","doi-asserted-by":"publisher","first-page":"D22","DOI":"10.1016\/j.jacc.2013.10.027","volume":"62","author":"A Vonk-Noordegraaf","year":"2013","unstructured":"Vonk-Noordegraaf A, Haddad F, Chin KM, Forfia PR, Kawut SM, Lumens J, Naeije R, Newman J, Oudiz RJ, Provencher S, et al. Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology. J Am Coll Cardiol. 2013;62:D22-33.","journal-title":"J Am Coll Cardiol"},{"key":"689_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0044485","author":"XR Zuo","year":"2012","unstructured":"Zuo XR, Wang Q, Cao Q, Yu YZ, Wang H, Bi LQ, Xie WP, Wang H. Nicorandil prevents right ventricular remodeling by inhibiting apoptosis and lowering pressure overload in rats with pulmonary arterial hypertension. PLoS ONE. 2012. https:\/\/doi.org\/10.1371\/journal.pone.0044485.","journal-title":"PLoS ONE"},{"key":"689_CR10","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1113\/expphysiol.2012.069096","volume":"98","author":"Z Wang","year":"2013","unstructured":"Wang Z, Chesler NC. Pulmonary vascular mechanics: important contributors to the increased right ventricular afterload of pulmonary hypertension. Exp Physiol. 2013;98:1267\u201373.","journal-title":"Exp Physiol"},{"key":"689_CR11","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1378\/chest.08-0492","volume":"135","author":"HJ Bogaard","year":"2009","unstructured":"Bogaard HJ, Abe K, Vonk Noordegraaf A, Voelkel NF. The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest. 2009;135:794\u2013804.","journal-title":"Chest"},{"key":"689_CR12","first-page":"2493","volume":"41","author":"F Sun","year":"2018","unstructured":"Sun F, Lu Z, Zhang Y, Geng S, Xu M, Xu L, Huang Y, Zhuang P, Zhang Y. Stage-dependent changes of \u03b22-adrenergic receptor signaling in right ventricular remodeling in monocrotaline-induced pulmonary arterial hypertension. Int J Mol Med. 2018;41:2493\u2013504.","journal-title":"Int J Mol Med"},{"key":"689_CR13","doi-asserted-by":"publisher","first-page":"5583","DOI":"10.1080\/21655979.2021.1967019","volume":"12","author":"J Wu","year":"2021","unstructured":"Wu J, Fu Y, Wu YX, Wu ZX, Wang ZH, Li P. Lycorine ameliorates isoproterenol-induced cardiac dysfunction mainly via inhibiting inflammation, fibrosis, oxidative stress and apoptosis. Bioengineered. 2021;12:5583\u201394.","journal-title":"Bioengineered"},{"key":"689_CR14","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/cvr\/cvw014","volume":"110","author":"M Zungu-Edmondson","year":"2016","unstructured":"Zungu-Edmondson M, Shults NV, Wong CM, Suzuki YJ. Modulators of right ventricular apoptosis and contractility in a rat model of pulmonary hypertension. Cardiovasc Res. 2016;110:30\u20139.","journal-title":"Cardiovasc Res"},{"key":"689_CR15","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.hfc.2011.08.010","volume":"8","author":"A Abbate","year":"2012","unstructured":"Abbate A, Narula J. Role of apoptosis in adverse ventricular remodeling. Heart Fail Clin. 2012;8:79\u201386.","journal-title":"Heart Fail Clin"},{"key":"689_CR16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cardiores.2005.04.012","volume":"67","author":"VP van Empel","year":"2005","unstructured":"van Empel VP, Bertrand AT, Hofstra L, Crijns HJ, Doevendans PA, De Windt LJ. Myocyte apoptosis in heart failure. Cardiovasc Res. 2005;67:21\u20139.","journal-title":"Cardiovasc Res"},{"key":"689_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.607384","volume":"11","author":"Z Yang","year":"2020","unstructured":"Yang Z, Sun H, Su S, Nan X, Li K, Jin X, Jin G, Li Z, Lu D. Tsantan Sumtang restored right ventricular function in chronic hypoxia-induced pulmonary hypertension rats. Front Pharmacol. 2020;11: 607384.","journal-title":"Front Pharmacol"},{"key":"689_CR18","first-page":"23","volume":"2018","author":"W Ren","year":"1829","unstructured":"Ren W, Gao S, Zhang H, Ren Y, Yu X, Lin W, Guo S, Zhu R, Wang W. Decomposing the mechanism of Qishen Granules in the treatment of heart failure by a quantitative pathway analysis method. Molecules. 1829;2018:23.","journal-title":"Molecules"},{"key":"689_CR19","doi-asserted-by":"publisher","first-page":"6636426","DOI":"10.1155\/2021\/6636426","volume":"2021","author":"H Huang","year":"2021","unstructured":"Huang H, Shan K, Cai M, Chen H, Wu F, Zhao X, Zhuang H, Li H, Shi S. \u201cYiqi Huayu, Wenyang Lishui\u201d Prescription (YHWLP) Improves the symptoms of chronic obstructive pulmonary disease-induced chronic pulmonary heart disease by inhibiting the RhoA\/ROCK signaling pathway. Evid Based Complement Alternat Med. 2021;2021:6636426.","journal-title":"Evid Based Complement Alternat Med"},{"key":"689_CR20","first-page":"746","volume":"17","author":"J Huang","year":"2019","unstructured":"Huang J, Xie Y, Li H, Zhang X, Huang Q, Zhu Y, Gu P, Jiang W. YQWY decoction reverses cardiac hypertrophy induced by TAC through inhibiting GATA4 phosphorylation and MAPKs. Chin J Nat Med. 2019;17:746\u201355.","journal-title":"Chin J Nat Med"},{"key":"689_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2021.114078","volume":"274","author":"J Wang","year":"2021","unstructured":"Wang J, Deng B, Liu J, Liu Q, Guo Y, Yang Z, Fang C, Lu L, Chen Z, Xian S, et al. Xinyang Tablet inhibits MLK3-mediated pyroptosis to attenuate inflammation and cardiac dysfunction in pressure overload. J Ethnopharmacol. 2021;274: 114078.","journal-title":"J Ethnopharmacol"},{"key":"689_CR22","first-page":"261","volume":"11","author":"YS Huang","year":"2000","unstructured":"Huang YS, Xian SX, Ding YQ, Lu LP, Chen YP, Wu H. Clinical study of Baoxinkang in treating congestive heart Failure with Qi-Yang deficiency. Traditional Chin Drug Res Clin Pharmacol. 2000;11:261\u20135.","journal-title":"Traditional Chin Drug Res Clin Pharmacol"},{"key":"689_CR23","unstructured":"Guo YN, JL, JY W, L Z, L Z, SX X, ZQ Y, LJ W, YS H: Study on Effect and Mechanism of Xinyang Tablet-containing Serum Regulating NLRP3-Mediated Pyrocytosis and Protecting Myocardial Cell Inflammation. Chinese Archives Traditional Chin Med. 2021. 39:92\u201397. Accessed Mar 2022"},{"key":"689_CR24","unstructured":"Luo CF, YS H, XY C, SX X, YD H, YD L: Effect of Baoxinkang on the expression of Bax and Bcl-2 protein in heart failure rat cardiomyocytes. J Guangzhou University of Traditional Chin Med. 2004. 21:5. [Accessed date: Aug., 2021]"},{"key":"689_CR25","first-page":"2","volume":"25","author":"CF Luo","year":"2006","unstructured":"Luo CF, Huang YS, Liu YC, Xian SX, Hong YD, Liu YD. Sequence changes of left ventricular hypertrophy in pressure overload rats and intervention effect of Baoxinkang. Inner Mongolia Traditional Chin Med. 2006;25:2.","journal-title":"Inner Mongolia Traditional Chin Med"},{"key":"689_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2019.112470","volume":"250","author":"Z Dang","year":"2020","unstructured":"Dang Z, Su S, Jin G, Nan X, Ma L, Li Z, Lu D, Ge R. Tsantan Sumtang attenuated chronic hypoxia-induced right ventricular structure remodeling and fibrosis by equilibrating local ACE-AngII-AT1R\/ACE2-Ang1-7-Mas axis in rat. J Ethnopharmacol. 2020;250: 112470.","journal-title":"J Ethnopharmacol"},{"key":"689_CR27","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.ijcard.2018.03.104","volume":"266","author":"F Chen","year":"2018","unstructured":"Chen F, Wang H, Lai J, Cai S, Yuan L. 3-Bromopyruvate reverses hypoxia-induced pulmonary arterial hypertension through inhibiting glycolysis: in vitro and in vivo studies. Int J Cardiol. 2018;266:236\u201341.","journal-title":"Int J Cardiol"},{"key":"689_CR28","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1159\/000497061","volume":"103","author":"YN Shi","year":"2019","unstructured":"Shi YN, Zhang XQ, Hu ZY, Zhang CJ, Liao DF, Huang HL, Qin L. Genistein protects H9c2 cardiomyocytes against chemical hypoxia-induced injury via inhibition of apoptosis. Pharmacology. 2019;103:282\u201390.","journal-title":"Pharmacology"},{"key":"689_CR29","first-page":"222","volume":"35","author":"LA Shimoda","year":"2020","unstructured":"Shimoda LA. Cellular pathways promoting pulmonary vascular remodeling by hypoxia. Physiology (Bethesda). 2020;35:222\u201333.","journal-title":"Physiology (Bethesda)"},{"key":"689_CR30","doi-asserted-by":"publisher","first-page":"3178","DOI":"10.1111\/jcmm.12871","volume":"21","author":"L Chen","year":"2017","unstructured":"Chen L, Liu P, Feng X, Ma C. Salidroside suppressing LPS-induced myocardial injury by inhibiting ROS-mediated PI3K\/Akt\/mTOR pathway in vitro and in vivo. J Cell Mol Med. 2017;21:3178\u201389.","journal-title":"J Cell Mol Med"},{"key":"689_CR31","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1093\/cvr\/cvx145","volume":"113","author":"CEE van der Bruggen","year":"2017","unstructured":"van der Bruggen CEE, Tedford RJ, Handoko ML, van der Velden J, de Man FS. RV pressure overload: from hypertrophy to failure. Cardiovasc Res. 2017;113:1423\u201332.","journal-title":"Cardiovasc Res"},{"key":"689_CR32","doi-asserted-by":"publisher","first-page":"540","DOI":"10.2165\/00003495-198836050-00003","volume":"36","author":"RN Brogden","year":"1988","unstructured":"Brogden RN, Todd PA, Sorkin EM. Captopril: an update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs. 1988;36:540\u2013600.","journal-title":"Drugs"},{"key":"689_CR33","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1476-9255-7-21","volume":"7","author":"JL Miguel-Carrasco","year":"2010","unstructured":"Miguel-Carrasco JL, Zambrano S, Blanca AJ, Mate A, V\u00e1zquez CM. Captopril reduces cardiac inflammatory markers in spontaneously hypertensive rats by inactivation of NF-kB. J Inflamm (Lond). 2010;7:21.","journal-title":"J Inflamm (Lond)"},{"key":"689_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.108780","volume":"113","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Zhang L, Fan X, Yang W, Yu B, Kou J, Li F. Captopril attenuates TAC-induced heart failure via inhibiting Wnt3a\/\u03b2-catenin and Jak2\/Stat3 pathways. Biomed Pharmacother. 2019;113: 108780.","journal-title":"Biomed Pharmacother"},{"key":"689_CR35","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12929-017-0359-3","volume":"24","author":"X Huang","year":"2017","unstructured":"Huang X, Wu P, Huang F, Xu M, Chen M, Huang K, Li GP, Xu M, Yao D, Wang L. Baicalin attenuates chronic hypoxia-induced pulmonary hypertension via adenosine A(2A) receptor-induced SDF-1\/CXCR4\/PI3K\/AKT signaling. J Biomed Sci. 2017;24:52.","journal-title":"J Biomed Sci"},{"key":"689_CR36","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1161\/HYPERTENSIONAHA.120.14931","volume":"76","author":"RK Sharma","year":"2020","unstructured":"Sharma RK, Oliveira AC, Yang T, Karas MM, Li J, Lobaton GO, Aquino VP, Robles-Vera I, de Kloet AD, Krause EG, et al. Gut pathology and its rescue by ACE2 (Angiotensin-Converting Enzyme 2) in hypoxia-induced pulmonary hypertension. Hypertension. 2020;76:206\u201316.","journal-title":"Hypertension"},{"key":"689_CR37","doi-asserted-by":"publisher","first-page":"8901","DOI":"10.3390\/ijms21238901","volume":"21","author":"JMM Kocken","year":"2020","unstructured":"Kocken JMM, da Costa Martins PA. Epigenetic regulation of pulmonary arterial hypertension-induced vascular and right ventricular remodeling: new opportunities? Int J Mol Sci. 2020;21:8901.","journal-title":"Int J Mol Sci"},{"key":"689_CR38","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1007\/s00204-015-1477-x","volume":"89","author":"YK Tham","year":"2015","unstructured":"Tham YK, Bernardo BC, Ooi JY, Weeks KL, McMullen JR. Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets. Arch Toxicol. 2015;89:1401\u201338.","journal-title":"Arch Toxicol"},{"key":"689_CR39","first-page":"2493","volume":"41","author":"F Sun","year":"2018","unstructured":"Sun F, Lu Z, Zhang Y, Geng S, Xu M, Xu L, Huang Y, Zhuang P, Zhang Y. Stagedependent changes of beta2adrenergic receptor signaling in right ventricular remodeling in monocrotalineinduced pulmonary arterial hypertension. Int J Mol Med. 2018;41:2493\u2013504.","journal-title":"Int J Mol Med"},{"key":"689_CR40","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1017\/S1047951115000402","volume":"26","author":"JG Schultz","year":"2016","unstructured":"Schultz JG, Andersen S, Andersen A, Nielsen-Kudsk JE, Nielsen JM. Evaluation of cardiac electrophysiological properties in an experimental model of right ventricular hypertrophy and failure. Cardiol Young. 2016;26:451\u20138.","journal-title":"Cardiol Young"},{"key":"689_CR41","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1089\/ham.2009.1065","volume":"11","author":"JS Windsor","year":"2010","unstructured":"Windsor JS, Rodway GW, Montgomery HE. A review of electrocardiography in the high altitude environment. High Alt Med Biol. 2010;11:51\u201360.","journal-title":"High Alt Med Biol"},{"key":"689_CR42","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.matbio.2018.01.010","volume":"68\u201369","author":"B Egemnazarov","year":"2018","unstructured":"Egemnazarov B, Crnkovic S, Nagy BM, Olschewski H, Kwapiszewska G. Right ventricular fibrosis and dysfunction: Actual concepts and common misconceptions. Matrix Biol. 2018;68\u201369:507\u201321.","journal-title":"Matrix Biol"},{"key":"689_CR43","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1023\/A:1020706316429","volume":"7","author":"KC Wollert","year":"2002","unstructured":"Wollert KC, Drexler H. Regulation of cardiac remodeling by nitric oxide: focus on cardiac myocyte hypertrophy and apoptosis. Heart Fail Rev. 2002;7:317\u201325.","journal-title":"Heart Fail Rev"},{"key":"689_CR44","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1172\/JCI118747","volume":"97","author":"E Teiger","year":"1996","unstructured":"Teiger E, Than VD, Richard L, Wisnewsky C, Tea BS, Gaboury L, Tremblay J, Schwartz K, Hamet P. Apoptosis in pressure overload-induced heart hypertrophy in the rat. J Clin Invest. 1996;97:2891\u20137.","journal-title":"J Clin Invest"},{"key":"689_CR45","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2021108690","author":"H Flores-Romero","year":"2022","unstructured":"Flores-Romero H, Hohorst L, John M, Albert MC, King LE, Beckmann L, Szabo T, Hertlein V, Luo X, Villunger A, et al. BCL-2-family protein tBID can act as a BAX-like effector of apoptosis. EMBO J. 2022. https:\/\/doi.org\/10.15252\/embj.2021108690.","journal-title":"EMBO J"},{"key":"689_CR46","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.yjmcc.2015.03.005","volume":"82","author":"X Huang","year":"2015","unstructured":"Huang X, Zou L, Yu X, Chen M, Guo R, Cai H, Yao D, Xu X, Chen Y, Ding C, et al. Salidroside attenuates chronic hypoxia-induced pulmonary hypertension via adenosine A2a receptor related mitochondria-dependent apoptosis pathway. J Mol Cell Cardiol. 2015;82:153\u201366.","journal-title":"J Mol Cell Cardiol"},{"key":"689_CR47","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1093\/cvr\/cvx159","volume":"113","author":"XQ Sun","year":"2017","unstructured":"Sun XQ, Abbate A, Bogaard HJ. Role of cardiac inflammation in right ventricular failure. Cardiovasc Res. 2017;113:1441\u201352.","journal-title":"Cardiovasc Res"},{"key":"689_CR48","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1161\/CIRCULATIONAHA.106.643585","volume":"115","author":"M Sun","year":"2007","unstructured":"Sun M, Chen M, Dawood F, Zurawska U, Li JY, Parker T, Kassiri Z, Kirshenbaum LA, Arnold M, Khokha R, et al. Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state. Circulation. 2007;115:1398\u2013407.","journal-title":"Circulation"},{"key":"689_CR49","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1161\/01.CIR.0000164237.58200.5A","volume":"111","author":"C Freund","year":"2005","unstructured":"Freund C, Schmidt-Ullrich R, Baurand A, Dunger S, Schneider W, Loser P, El-Jamali A, Dietz R, Scheidereit C, Bergmann MW. Requirement of nuclear factor-kappaB in angiotensin II- and isoproterenol-induced cardiac hypertrophy in vivo. Circulation. 2005;111:2319\u201325.","journal-title":"Circulation"},{"key":"689_CR50","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.cyto.2017.11.015","volume":"107","author":"B Jude","year":"2018","unstructured":"Jude B, Vetel S, Giroux-Metges MA, Pennec JP. Rapid negative inotropic effect induced by TNF-\u03b1 in rat heart perfused related to PKC activation. Cytokine. 2018;107:65\u20139.","journal-title":"Cytokine"},{"key":"689_CR51","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1161\/HYPERTENSIONAHA.109.148635","volume":"56","author":"GC Mel\u00e9ndez","year":"2010","unstructured":"Mel\u00e9ndez GC, McLarty JL, Levick SP, Du Y, Janicki JS, Brower GL. Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension. 2010;56:225\u201331.","journal-title":"Hypertension"},{"key":"689_CR52","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40709-021-00147-4","volume":"28","author":"M Li","year":"2021","unstructured":"Li M, Li K, Ren Y. Nesfatin-1 protects H9c2 cardiomyocytes against cobalt chloride-induced hypoxic injury by modulating the MAPK and Notch1 signaling pathways. J Biol Res (Thessalon). 2021;28:21.","journal-title":"J Biol Res (Thessalon)"}],"container-title":["Chinese Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-022-00689-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13020-022-00689-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-022-00689-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T14:06:02Z","timestamp":1670249162000},"score":1,"resource":{"primary":{"URL":"https:\/\/cmjournal.biomedcentral.com\/articles\/10.1186\/s13020-022-00689-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,5]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["689"],"URL":"https:\/\/doi.org\/10.1186\/s13020-022-00689-2","relation":{},"ISSN":["1749-8546"],"issn-type":[{"value":"1749-8546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,5]]},"assertion":[{"value":"16 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Animal Care and Use Committee of Academy of Military Medical research institute.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"134"}}